Edwyn
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | $2,147 | $2,832 | $2,887 | $2,950 | $2,893 |
| Gross Profit | $768 | $1,176 | $1,136 | $1,129 | $999 |
| Operating Income | $407 | $752 | $734 | $676 | $570 |
| Net Income | $346 | $662 | $586 | $593 | $493 |
Over the five-year period, WEST PHARMACEUTICAL SERVICES, INC. experienced significant revenue growth from 2020 to 2021, with revenues increasing nearly 32% from approximately 2147 million USD to 2832 million USD. This jump was coupled with a notable rise in operating income from 407 million USD to 752 million USD—an increase of over 85%—and a strong improvement in net income, which climbed from 346 million USD to 662 million USD. These pronounced year-over-year increases in 2021 suggest that the company may have benefited from favorable market conditions or operational enhancements, enabling improvements in both cost management and profitability margins. Since 2021, however, growth appears to have moderated with revenues rising modestly to 2949 million USD in 2023 before a slight decline to 2893 million USD in 2024. Gross profit peaked in 2021 at 1176 million USD but then declined steadily, reaching 998.5 million USD in 2024. This downward movement is mirrored in operating income and net income, with their respective figures dropping to 569.9 million USD and 492.7 million USD by 2024. The absence of further year-over-year swings greater than 20% beyond the strong 2021 performance points to a normalization phase after an exceptional growth year. Overall, while the company’s financial health remains solid given its sustained revenue base and profitability, the deceleration in growth and downward trend in margins in the later years call for a closer look at cost control and market dynamics to ensure long-term sustainability.
This analysis is for informational purposes only and does not constitute financial advice or recommendations for any investment decisions. Please consult with a qualified financial professional for personalized guidance.